Phase 2 Study.Tailored Therapy for Hodgkin Lymphoma Based on Predefined Risk Factors and Early Interim PET/CT for Response Assessment and Further Therapy Decisions.
study aim is to tailor the therapy in order to administer the lowest cumulative dose of
therapy yet considered safe in order to reduce both early and late therapy related
patients will be divided according to risk factors to sub groups of early favorable, early
unfavorable, advanced disease with score less then 3 points or higher then 3 points.
Early Interim PET will be carried out Further therapy will be based on the study results.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Event Free survival in various risk groups of patients
Eldad J Dann, MD
RABMAM medical center ,Haifa Israel , Rappapport school of medicine Technion Israel technical Institute Haifa Israel
Israel: Israeli Health Ministry Pharmaceutical Administration